ISDA

Entry Detail

PDB ID:

6NY4

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2019-02-11

Release Date:

2019-05-22

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.33 Å

R-Value Free:

0.24

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase JAK3
Mutations:C811S,C1040S,C1048S
Chain IDs:A
Chain Length:293
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P52333 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

Z3A

Primary Citation

Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.

Spergel, S.H, Mertzman, M.E, Kempson, J, Guo, J, Stachura, S, Haque, L, Lippy, J.S, Zhang, R.F, Galella, M, Pitt, S, Shen, G, Fura, A, Gillooly, K, McIntyre, K.W, Tang, V, Tokarski, J, Sack, J.S, Khan, J, Carter, P.H, Barrish, J.C, Nadler, S.G, Salter-Cid, L.M, Schieven, G.L, Wrobleski, S.T, Pitts, W.J.Show

Acs Med.Chem.Lett. 10 306 311 (2019)

PMID: 30891131 DOI: 10.1021/acsmedchemlett.8b00508

Abstact

The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib 1, has been approved in the United States for use in rheumatoid arthritis (RA) patients. A number of JAK inhibitors with a variety of JAK family selectivity profiles are currently in clinical trials. Our goal was to identify inhibitors that were functionally selective for JAK1 and JAK3. Compound 22 was prepared with the desired functional selectivity profile, but it suffered from poor absorption related to physical properties. Use of the phosphate prodrug 32 enabled progression to a murine collagen induced arthritis (CIA) model. The demonstration of a robust efficacy in the CIA model suggests that use of phosphate prodrugs may resolve issues with progressing this chemotype for the treatment of autoimmune diseases such as RA.

Legend

Protein

Chemical

Disease

Primary Citation of related structures